目次

Table of Content

1. Introduction To CD39 Targeting Therapies
1.1 Overview
1.2 Role of CD39 and Emergence As Therapeutic Target
1.3 Discovery of CD39 and Development Of Targeting Therapies

2. CD39 Targeting Therapies Mechanism Of Action
2.1 CD39 Inhibition
2.2 CD39 Agonism

3. Current CD39 Targeting Therapy Approaches
3.1 Antibodies
3.2 Nucleic Acid Therapeutics
3.3 Small Molecule Inhibitors

4. Global CD39 Targeted Therapies Clinical Trials Overview
4.1 By Company
4.2 By Indication
4.3 By Country
4.4 By Phase

5. CD39 Targeted Therapies Clinical Trials Insight By Company, Country, Indication and Phase
5.1 Research
5.2 Preclinical
5.3 Phase I
5.4 Phase II

6. Global CD39 Targeting Therapy Market Trends and Developments
6.1 Current Market Outline
6.2 Future Market Opportunities

7. Role Of CD39 Targeting Therapies By Indication: Clinical Development and Collaborations
7.1 Cancer
7.2 Autoimmune and Inflammatory Diseases
7.3 Cardiovascular Diseases
7.4 Infections

8. CD39 Targeted Therapies Technology Platforms
8.1 OligoCreator and LNAplus Platforms - Secarna Pharmaceuticals
8.2 Unnamed Platforms - Biotheus
8.3 Unnamed Platform - Adimab
8.4 OriAb Antibody Discovery Platform - Oricell Therapeutics
8.5 TMAb Platform - Sensei Biotherapeutics

9. Global CD39 Targeted Therapies Market Dynamics
9.1 Market Drivers and Opportunities
9.2 Market Challenges and Restraints

10. Competitive Landscape
10.1 Adimab
10.2 Arcus Biosciences
10.3 Biotheus
10.4 BrightPath Biotherapeutics
10.5 Elpiscience Biopharmaceuticals
10.6 Innate Pharma
10.7 Orega Biotech
10.8 OriCell Therapeutics
10.9 Secarna Pharmaceuticals
10.10 Trishula Therapeutics

List of Figures
Figure 1-1: CD39/CD73/A2AR Pathway
Figure 1-2: Role Of Adenosine In Immune Regulation
Figure 1-3: Effects Of CD39 and Adenosine On Immune Cells
Figure 1-4: Discovery Of CD39 and Developmental Milestones
Figure 2 -1: CD39 Inhibition - Mechanism
Figure 2-2: CD39 Agonism - Mechanism
Figure 3-1: TTX-030: Mechanism of Action
Figure 3-2: Oligonucleotides - Benefits
Figure 4-1: Global - CD39 Targeted Therapies In Clinical Trials By Company (Number), 2025
Figure 4-2: Global - CD39 Targeted Therapies In Clinical Trials By Indication (Number), 2025
Figure 4-3: Global - CD39 Targeted Therapies In Clinical Trials By Country (Number), 2025
Figure 4-4: Global - CD39 Targeted Therapies In Clinical Trials By Phase (Number), 2025
Figure 7-1: Role Of CD39 In Cancer
Figure 7-2: ARC-25 Phase I/Ib (NCT05891171) Study - Initiation and Completion Year
Figure 7-3: MATISSE Phase II (NCT05742607) Study - Initiation and Completion Year
Figure 7-4: ELTIVATE/TTX-030-003 Phase II (NCT06119217) Study - Initiation and Completion Year
Figure 7-5: ES014-IIT-01 Phase II (NCT06543056) Study - Initiation and Completion Year
Figure 7-6: Role Of CD39 In Modulating Inflammatory Responses
Figure 7-7: Role Of CD39 In Cardiovascular Diseases
Figure 7-8: Role Of CD39 In Infections
Figure 8-1: Secarna Pharmaceuticals - OligoCreator Platform
Figure 8-2: Adimab - Proprietary Platform
Figure 8-3: Sensei Biotherapeutics - TMAb Platform
Figure 9-1: Global CD39 Targeted Therapies Market - Market Drivers and Opportunities
Figure 9-2: Global CD39 Targeted Therapies Market - Market Challenges and Restraints